Abevmy 100 and 400 mg is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.
Biocon Biologics, a subsidiary of Biocon announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authoris ation of their biosimilar Bevacizumab ...